Home / Business / Bristol-Myers shareholder opposes Celgene deal

Bristol-Myers shareholder opposes Celgene deal



One of Bristol-Myers Squibb Co.'s major shareholders opposes the company's $ 74 billion deal on the purchase of competitor Celgene Corp., becoming the latest investor to express its dissatisfaction with this transaction.

Wellington Management Co., an investment company holding a stake of about 8% in Bristol-Myers, said on Wednesday that the agreement required shareholders to take too many risks and offered Bristol shares. cheaper to Celgene shareholders. The company also said that the execution of a successful transaction could be more difficult than expected by management ….


Source link